San Diego, CA -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced the launch of the Be a Flu Fighter initiative, aimed at increasing awareness and prevention of influenza. Recognizing that schools and hospitals are important centers for health-related information, the Be a Flu Fighter initiative is designed to communicate that everyone can help prevent the spread of flu by taking just a few simple precautions.
BD has designed the Be a Flu Fighter initiative to enhance the ability of healthcare professionals at schools, hospitals, laboratories and other public/private settings to help slow the predicted, rapid spread of influenza by promoting good hygiene, vaccination and other flu prevention strategies. With straightforward, accessible language and graphics, the complimentary, printer-friendly materials can be easily downloaded from www.bd.com/ds/flufighter. The BD site also provides hospitals and laboratories with informational materials designed to help professionals properly obtain and handle specimens for flu diagnosis.
"As a world leader in healthcare, BD is pleased to provide these much-needed resources. Our role goes beyond providing quality products, and includes enabling healthcare professionals to effectively spread the word about practices that can lead to better prevention, diagnosis and therapy for infectious diseases, such as influenza," said Tobi Karchmer, MD, Medical Director, BD Diagnostics.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
